logging in or signing up dosage regimen rmnjrddy Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 131 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: October 29, 2013 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript DOSAGE REGIMENS: DOSAGE REGIMENS By Dr. Ramanjireddy Tatiparthi JIMMA UNIVERSITY DESIGN OF DOSAGE REGIMENS (empirical & kinetic approaches): DESIGN OF DOSAGE REGIMENS (empirical & kinetic approaches) Dosage regimen is defined as the manner in which a drug is taken. For some drugs like analgesics, hypnotics, antiemetics , etc., a single dose may provide effective treatment. However, the duration of most illnesses is longer than the therapeutic effect produced by a single dose. In such cases, drugs are required to be taken on a repetitive basis over a period of time depending upon the nature of illness. Thus, for successful therapy, design of an optimal multiple dosage regimen is necessary. An optimal multiple dosage regimen is the one in which the drug is administered in suitable doses (by a suitable route), with sufficient frequency that ensures maintenance of plasma concentration within the therapeutic window (without excessive fluctuations and drug accumulation) for the entire duration of therapy. Approaches to design of dosage regimen : Approaches to design of dosage regimen The various approaches employed in designing a dosage regimen are – 1. Empirical Dosage Regimen – is designed by the physician based on empirical clinical data, personal experience and clinical observations. This approach is, however, not very accurate. 2. Individualized Dosage Regimen – is the most accurate approach and is based on the pharmacokinetics of drug in the individual patient. The approach is suitable for hospitalised patients but is quite expensive. 3. Dosage Regimen on Population Averages – This is the most often used approach. The method is based on one of the two models – Fixed model – here, population average pharmacokinetic parameters are used directly to calculate the dosage regimen. Adaptive model – is based on both population average pharmacokinetic parameters of the drug as well as patient variables such as weight, age, sex, body surface area and known patient pathophysiology such as renal disease. PowerPoint Presentation: In designing a dosage regimen based on population averages — It is assumed that all pharmacokinetic parameters of the drug remain constant during the course of therapy once a dosage regimen is established. The same becomes invalid if any change is observed. The calculations are based on open one-compartment model which can also be applied to two compartment model if is used instead of K E , and V d,ss instead of V d while calculating the regimen. Irrespective of the route of administration and complexity of pharmacokinetic equations, the two major parameters that can be adjusted in developing a dosage regimen are — 1. The dose size — the quantity of drug administered each time , and 2. The dosing frequency — the time interval between doses . Dose Size: Dose Size The magnitude of both therapeutic and toxic responses depends upon dose size. Dose size calculation also requires the knowledge of amount of drug absorbed after administration of each dose. Greater the dose size, greater the fluctuations between Css,max and Css,min during each dosing interval and greater the chances of toxicity. Schematic representation of influence of dose size on plasma concentration-time profile after oral administration of a drug at fixed intervals of time. DOSING FREQUENCY: DOSING FREQUENCY The dose interval (inverse of dosing frequency ) is calculated on the basis of half-life of the drug. If the interval is increased and the dose is unchanged, Cmax, Cmin & Cavg decrease but the ratio Cmax/ Cmin increases. Opposite is observed when dosing interval is reduced or dosing frequency increased. It also results in greater drug accumulation in the body and toxicity Schematic representation of the influence of dosing frequency on plasma concentration-time profile obtained after oral administration of fixed doses of a drug. PowerPoint Presentation: A proper balance between both dose size & dosing frequency is often desired to attain steady-state concentration with minimum fluctuations and to ensure therapeutic efficacy and safety. The same cannot be obtained by giving larger doses less frequently. However, administering smaller doses more frequently results in smaller fluctuations. Every subsequent dose should be administered at an interval equal to half-life of the drug. A rule of thumb is that – 1. For drugs with wide therapeutic index such as penicillin, larger doses may be administered at relatively longer intervals (more than the half-life of drug) without any toxicity problem 2. For drugs with narrow therapeutic index such as digoxin , small doses at frequent intervals (usually less than the half-life of the drug) is better to obtain a profile with least fluctuations which is similar to that observed with constant rate infusion or controlled-release system. PowerPoint Presentation: Drug Accumulation During Multiple Dosing PowerPoint Presentation: Consider the amount of drug in the body-time profile obtained after i.v . multiple dosing with dosing interval equal to one t½. After the administration of first dose Xo at t = 0, the amount of drug in the body will be X = 1Xo. At the next dosing interval when X = ½Xo, the amount of drug remaining in the body, administration of the next i.v . dose raises the body content to X = Xo + ½Xo i.e. drug accumulation occurs in the body. Thus, accumulation occurs because drug from previous doses has not been removed completely . As the amount of drug in the body rises gradually due to accumulation, the rate of elimination also rises proportionally until a steady-state or plateau is reached when the rate of drug entry into the body equals the rate of exit. PowerPoint Presentation: The maximum and minimum values of X i.e. Xss,max and Xss,min approach respective asymptotes at plateau. It is interesting to note that at plateau, Xss,min = 1Xo and Xss,max = 2Xo i.e. Xss,min equals the amount of drug in the body after the first dose and Xss,max equals twice the first dose. Also ( Xss,max – Xss,min ) = Xo and Xss,max / Xss,min = 2. All this applies only when t = t½ and drug is administered intravenously. When t < t½, the degree of accumulation is greater and vice-versa. Thus, the extent to which a drug accumulates in the body during multiple dosing is independent of dose size, and is a function of – Dosing interval, and Elimination half-life. The extent to which a drug will accumulate with any dosing interval in a patient can be derived from information obtained with a single dose and is given by accumulation index Rac as: Time to reach steady-state during multiple dosing: Time to reach steady-state during multiple dosing The time required to reach steady-state depends primarily upon the half-life of the drug. It also means that the rate at which the multiple dose steady-state is reached is determined only by K E . The time taken to reach steady-state is independent of dose size, dosing interval and number of doses. Maximum and Minimum Concentration During Multiple Dosing If n is the number of doses administered, the Cmax and Cmin obtained on multiple dosing after the nth dose is given as: The maximum and minimum concentration of drug in plasma at steady-state are found by following equations: where Co = concentration that would be attained from instantaneous absorption and distribution (obtained by extrapolation of elimination curve to time zero). PowerPoint Presentation: Fluctuation is defined as the ratio Cmax/ Cmin . Greater the ratio, greater the fluctuation. Like accumulation, it depends upon dosing frequency and half-life of the drug. It also depends upon the rate of absorption. The greatest fluctuation is observed when the drug is given as i.v . Bolus. Fluctuations are small when the drug is given extravascularly because of continuous absorption. Loading and Maintenance Doses A drug does not show therapeutic activity unless it reaches the desired steady-state. It takes about 5 half-lives to attain it and therefore the time taken will be too long if the drug has a long half-life. Plateau can be reached immediately by administering a dose that gives the desired steady-state instantaneously before the commencement of maintenance doses Xo. Such an initial or first dose intended to be therapeutic is called as priming dose or loading dose A simple equation for calculating loading dose is: PowerPoint Presentation: After e.v . administration, Cmax is always smaller than that after i.v . administration and hence loading dose is proportionally smaller. For drugs having low therapeutic indices, the loading dose may be divided into smaller doses to be given at various intervals before the first maintenance dose. When V d is not known, loading dose may be calculated by the following equation: The above equation applies when K a >> K E and drug is distributed rapidly. When the drug is given i.v . or when absorption is extremely rapid, the absorption phase is neglected and the above equation reduces to accumulation index : PowerPoint Presentation: The ratio of loading dose to maintenance dose X o,L /X o is called as dose ratio . As a rule, when t = t½, dose ratio should be equal to 2.0 but must be smaller than 2.0 when t > t½ and greater when t < t½. If loading dose is not optimum, either too low or too high, the steady-state is attained within approximately 5 half-lives in a manner similar to when no loading dose is given. Schematic representation of plasma concentration-time profiles that result when dose ratio is greater than 2.0, equal to 2.0 and smaller than 2.0. Maintenance of drug within the therapeutic range: Maintenance of drug within the therapeutic range The ease or difficulty in maintaining drug concentration within the therapeutic window depends upon — 1. The therapeutic index of the drug 2. The half-life of the drug 3. Convenience of dosing. It is extremely difficult to maintain such a level for a drug with short half-life (less than 3 hours) and narrow therapeutic index e.g. heparin, since the dosing frequency has to be essentially less than t½. However, drugs such as penicillin (t½ = 0.9 hours) with high therapeutic index may be given less frequently (every 4 to 6 hours) but the maintenance dose has to be larger so that the plasma concentration persists above the minimum inhibitory level. PowerPoint Presentation: A drug with intermediate t½ (3 to 8 hours) may be given at intervals t £ t½ if therapeutic index is low and those with high indices can be given at intervals between 1 to 3 half-lives. Drugs with half-lives greater than 8 hours are more convenient to dose. Such drugs are usually administered once every half-life. Steady-state in such cases can be attained rapidly by administering a loading dose. For drugs with very long half-lives (above 24 hours) e.g. amlodipine , once daily dose is very convenient. Design of dosage regimen from plasma concentrations: Design of dosage regimen from plasma concentrations If the therapeutic range, apparent V d and clearance or half-life of a drug is known, then dosage regimen can be designed to maintain drug concentration within the specified therapeutic range. The latter is defined by lower limit ( C lower ) and an upper limit (C upper ). The maximum dosing interval, which ideally depends upon the therapeutic index (can be defined as a ratio of C upper to C lower ) and elimination half-life of the drug, can be expressed by equations Understandably, the dosing interval selected is always smaller than tmax. The maximum maintenance dose Xo,max that can be given every tmax is expressed as: You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.